Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
- Conditions
- Pregnancy RelatedCOVID-19Influenza, Human
- Interventions
- Procedure: Blood sample
- Registration Number
- NCT04568044
- Lead Sponsor
- Imperial College London
- Brief Summary
The proposed study is designed to investigate if and how pregnant women infected with Coronavirus Disease-19 (COVID-19) infection go on to develop long-term immunity. In December 2019, a group of people in Wuhan, China presented with symptoms of a pneumonia of an unknown cause that led to the discovery of a new coronavirus called COVID-19. COVID-19 has caused a global pandemic with 7,140,000 confirmed cases and 418,000 deaths as of 13th June 2020. In the United Kingdom (UK), there have been 294,000 cases and 41,662 deaths as of 13th June 2020. In humans, this infection primarily involves the upper part of the lungs, but it can also affect other organs. It causes mild symptoms in the majority of people affected but some people can have severe infections, with some even requiring critical care in hospital. During Severe acute respiratory syndrome (SARS), a previous coronavirus epidemic, pregnant women were disproportionately affected with severe illness. Understanding how the immune system responds long-term to this infection may hold the key to developing better vaccines and efficient treatment plans. Specialised immunity develops when individuals are infected by this and other viruses. The investigators of this study propose that, in pregnancy, this specialised immunity may not behave effectively. This may affect their ability to develop long lasting immunity and make them more vulnerable to re-infection. In this study, the investigators aim to recruit patients across 6 groups including COVID-19 newly infected pregnant women, and people with differing illness severity, mild to moderate, severe/critical, no infection (controls), as well as pregnant women with influenza and those receiving influenza vaccine. The study team will compare COVID-19 in pregnancy with non-pregnant infected and with influenza infected and vaccinated pregnant women. The study team will consent patients in all of these groups to provide a series of blood samples at different time points in a 12-month period.
- Detailed Description
Background
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), commonly known as Coronavirus Disease-19 (COVID-19), is a global pandemic with 7,410,000 confirmed cases and 418,000 deaths as of 13th June 2020. It is believed that SARS-CoV-2 shares 79.6% of its sequence identity with SARS-CoV and resembles some clinical outcomes like viral pneumonia. However, it causes milder symptoms in majority of people infected, and can be an asymptomatic infection in some individuals. Just in the 21st century, we have seen three major coronavirus (CoV) outbreaks: SARS-CoV, Middle East respiratory syndrome (MERS)-CoV, and the novel SARS-CoV-2, which have resulted in many deaths and have posed a real threat to public health. In fact, during SARS more pregnant women required intensive care and ventilation, and the number of deaths was higher when compared to non-pregnant adults. This is partly because in pregnancy, the risk of viral pneumonia is greater compared to the general population.
Understanding T and B cell mediated immunity in COVID-19 participants may hold the key to developing better vaccines and efficient treatment plans. To date there is only one study that has investigated circulatory T follicular helper cells (cTFH), which like there germinal centre counterparts are a specialised effector cluster of differentiation 4 (CD4) T cell that induces B cell activation, and differentiation into class-switched and antibody secreting long-lasting plasmablasts. This study observed an increase in cTFH during pregnancy. However, studies in older patients, which comprise another high risk group, have shown mixed results with cTFH showing lower levels of activation. This will impact on long term antibody production following infection or vaccination. We propose that circulatory cTFH, and B cells may not be as activated in both pregnant women and patients with severe to critical patients when compared with mild to moderate patients resulting in less or poorly functioning anti-SARS-CoV-2 antibodies. Therefore, we expect in infected pregnant individuals the development of long-term immunity may be worse when compared to non-pregnant people with similar disease severity, making them more susceptible to re-infection. Compared to influenza, which is another respiratory illness with significant morbidity in pregnancy and has a current vaccination program, we expect that the same measures of immunity will be less pronounced post COVID-19 infection. Furthermore, the development of long-term immunity will be less effective in patients with severe illness, who for the most part, comprise a particularly high-risk group including the elderly and patients with multiple comorbidities. It is vital that we expand our knowledge of long-lasting immunity in individuals who have recovered from COVID-19 to see how long these individuals are protected against re-infection and whether they develop long lasting immunity. Moreover, there is no current research establishing the parameters of seroprotective immunity. Previous research has suggested that SARS-CoV specific Immunoglobin G (IgG) declines significantly within 2 years with some reports showing a complete loss within 6 years in most SARS-CoV recovered patients. This may equate to a loss of long-term protection. The investigators of this study propose measuring SARS-CoV-2 specific IgG levels by doing memory B cell (Enzyme-Linked ImmunoSpot) ELISpots and comparing the data with cTFH and B cell flow cytometry panels. The research team will be able to profile the generation and persistence of protective antibodies produced by infected individuals who go on to recover. The findings from this study will generate hypotheses to be tested in larger studies of COVID-19 recovered pregnant patients, and also assist researchers working trying to understand the effectiveness of the vaccines in pregnancy once these become commercially available.
Research Question
In pregnant individuals who have recovered from COVID-19:
A. How long will their SARS-CoV-2 specific Immunoglobulin G (IgG) levels remain in peripheral blood, what is the rate of decline and how does this compare to non-pregnant individuals?
B. How did their T cell mediated immune function differ from non-pregnant patients during the infection?
C. How do their SARS-CoV-2 specific memory T cell differ when compared to severe to non-pregnant patients' post-recovery?
D. How does antibody production, and B and T cell function post COVID-19 infection in pregnancy compare with influenza infection and vaccination?
Hypothesis
The investigators hypothesise that pregnant patients with COVID-19 will develop a less robust and measurable B-cell response when compared to influenza infected/vaccinated women and non-pregnant individuals, and that their seroprotective antibody responses will decline by 12 months post infection.
Study Aims
A. Establish robust assays to measure SARS-CoV-2-specific IgG from individuals who have recovered from COVID-19 infection and track these levels over a 12-month period to measure any decline. In pregnancy, compare this to influenza antibodies produced after infection and vaccination.
B. Measure frequency of activated cTFH, and antigen-secreting cells (ASCs) at days 7-14 of symptom onset in pregnant patients with COVID-19 and compare with non-pregnant groups, and pregnant influenza infected and influenza vaccinated. In addition, compare between non-pregnant groups with mild to moderate symptoms when compared to severe to critical patients.
C. Measure frequency of activated memory B cells at day 28 in pregnant patients with COVID-19 and compare with non-pregnant groups, and pregnant influenza infected and influenza vaccinated. In addition, compare between non-pregnant groups with mild to moderate symptoms when compared to severe to critical patients.
D. Measure frequency of CD4 and cluster of differentiation 8 (CD8) T cells in pregnant patients with COVID-19 and compare with non-pregnant groups, and pregnant influenza infected and influenza vaccinated. In addition, compare between non-pregnant groups with mild to moderate symptoms when compared to severe to critical patients.
E. Quantify antigen-specific memory T cells and measure frequency of activated T cells in all patient groups.
F. Quantification of SARS-CoV-2 viral load from infected participants.
Study Design
This study will be a prospective observational project to investigate the potential decline of protective immunity in pregnancy after participants have recovered from SARS-CoV-2. The research team will compare these findings with non-pregnant patients who have had COVID-19 and developed mild to moderate symptoms or severe to critical participants. Patients who go on to join a SARS-CoV-2 vaccine trial will not be excluded but the vaccination date will be recorded, and their results interpreted accordingly. In order to compare COVID-19 infection with another respiratory infection and assess long term protective immunity with an intervention already in place in this patient group designed to provide seroprotective antibodies, the investigators will investigate influenza and influenza vaccine. Therefore, data from pregnant patients will also be compared with influenza infected pregnant women and those who have received the influenza vaccination.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 128
-
Group A: Mild to moderate COVID-19 (non-pregnant)
• Current male or female COVID-19 infected (age 18-60 years old) with mild to moderate illness
-
Group B: Severe to critical COVID-19 (non-pregnant)
• Current male or female COVID-19 infected (age 18-60 years old) with severe to critical illness
-
Group C: Controls (non-pregnant)
• Male of female uninfected (age 18-60 years old) who have no history of COVID-19 symptoms or illness
-
Group D: Pregnant or postnatal with COVID-19
- Current pregnant or postnatal COVID-19 infected (age 18-50 years old)
- Pregnant or postnatal (within 6 weeks since birth) who were diagnosed with COVID-19 less than 4 months previously (age 18-50 years old)
- Singleton pregnancy
-
Group E: Pregnant or postnatal with influenza
- Current pregnant or postnatal influenza infected (age 18-50 years old)
- Pregnant or postnatal (within 6 weeks since birth) who were diagnosed with influenza less than 4 months previously (age 18-50 years old)
- Singleton pregnancy
-
Group F: Pregnant and have received the influenza vaccine
- Current pregnant who has received the influenza vaccine (age 18-50 years old)
- Singleton pregnancy
-
Group A, Group B and Group C:
- Patients unable to understand verbal or written information in English, regarding the study. Lack of capacity to consent at the point of recruitment
- Pregnant
- Participants who have previously been part of any SARS-CoV-2 vaccine trial
- Evidence of HIV infection
- Participants on medication that may significantly affect their immune system such as chemotherapy drugs
- Vulnerable patients with known safe-guarding issues
- Pregnant with more than one baby
-
Group D, E and F:
- Patients unable to understand verbal or written information in English, regarding the study.
- Lack of capacity to consent at the point of recruitment
- Participants who have previously been part of any SARS-CoV-2 vaccine trial
- Evidence of HIV infection
- Participants on medication that may significantly affect their immune system such as chemotherapy drugs other than steroids, which have been given for fetal lung maturity
- Vulnerable patients with known safe-guarding issues
- Pregnant with more than one baby
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group B: Severe to critical COVID-19 (non-pregnant) Blood sample Current male or female COVID-19 infected (age 18-60 years old) with severe to critical illness. Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months). Group C: Controls (non-pregnant) Blood sample Male of female uninfected (age 18-60 years old) who have no history of COVID-19 symptoms or illness. A blood sample will be taken on 1 day and at 1 time point. Group E: Pregnant or postnatal with influenza Blood sample Current pregnant or postnatal influenza infected (age 18-50 years old). Singleton pregnancies only. Blood samples over 12 months and 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months). Group A: Mild to moderate COVID-19 (non-pregnant) Blood sample Current male or female COVID-19 infected (age 18-60 years old) with mild to moderate illness. Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months). Group F: Pregnant and have received the influenza vaccine Blood sample Current pregnant and due to receive the influenza vaccine (age 18-50 years old). Singleton pregnancies only. Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine). Group D: Pregnant or postnatal with COVID-19 Blood sample Current pregnant or postnatal COVID-19 infected (age 18-50 years old) Pregnant or postnatal who were diagnosed with COVID-19 less than 8 months previously (age 18-50 years old). Singleton pregnancies only. For most participants in this group, blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months). However, for pregnant women admitted to hospital with severe COVID-19, we will aim to collect earlier timepoints (day 1-3, day 5-7 and then day 7-14). Thereafter, we will follow the above mentioned the long-term schedule (i.e. 1, 4, 8, 12 months).
- Primary Outcome Measures
Name Time Method Quantification of SARS-CoV-2 specific IgG production by memory B cells to measure long-lasting immune protection against re-infection. Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection. Group C: 1 day. 1 time point. B cell ELISpot assay and quantify Immunoglobulin A (IgA) and IgG using Enzyme-linked immunosorbent assay (ELISA) from plasma and/or serum from COVID-19 recovered individuals.
Phenotyping antibody secreting cells (ASCs) and memory B cells during COVID-19 infection, and post recovery. Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection. Group C: 1 day. 1 time point. Devise a flow cytometry panel to phenotype B cells.
- Secondary Outcome Measures
Name Time Method In pregnancy, comparing antibody production, and immune phenotype and function (as outlined above) between COVID-19 infection, and influenza infected or vaccinated. Groups A, B, D, E and F: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection/vaccination. Group C: 1 day. 1 time point. Parameters including antibody titres, cTFH and memory B cell and ASC proportions, and T cell function will be compared between COVID-19 infected, and influenza infected and vaccinated pregnant women.
Quantification of SARS-COV-2 viral load using PCR. Groups A, B, D: at 7-14 days and during recovery phase. Group C: 1 day. 1 time point. Use real-time PCR (RT-PCR) and nested PCR to detect SARS-CoV-2 viral load
Investigating T cell mediated immune function post COVID-19 Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection/vaccination. Group C: 1 day. 1 time point. Use a combination of flow cytometry, enzyme-linked immunospot (ELISpot) assays, and DNA/RNA analysis.
Immuno-phenotype circulatory T follicular helper cells (cTFH) cells post SARS-CoV-2 infection. Groups A, B, D: at 7-14 days post infection or vaccination. Group C: 1 day. 1 time point. Devise a flow cytometry panel to phenotype cTFH cells.
Trial Locations
- Locations (2)
Chelsea and Westminster NHS Foundation Trust
🇬🇧London, United Kingdom
Imperial College Healthcare NHS Trust
🇬🇧London, United Kingdom